Navigation Links
NYSE Amex LLC Accepts Plan of Compliance of The Quantum Group, Inc.

WELLINGTON, Fla., June 3 /PRNewswire-FirstCall/ -- The Quantum Group, Inc. (NYSE Amex: QGP) (the "Company"), announced today that on May 28, 2009, the NYSE Amex LLC (the "Exchange") accepted the Company plan of compliance with respect to its previously disclosed listing deficiency as set forth in Section 1003(a)(iv) of the Exchange Company Guide. The Company was afforded the opportunity to submit a plan of compliance to the Exchange and on April 15, 2009 presented its plan to the Exchange, with subsequent submissions to the plan. On May 28, 2009, the Exchange notified the Company that it accepted the Company plan of compliance and granted the Company an extension until September 17, 2009, to regain compliance with the continued listing standards. The Company will be required to provide the Exchange staff with updates in conjunction with the initiatives of the plan of compliance as appropriate or upon the Exchange's request and the Exchange staff will review the Company periodically for compliance with the plan of compliance during the extension period. Failure to make progress consistent with the plan of compliance or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

About The Quantum Group, Inc.

The Quantum Group is an innovation-driven Healthcare Services Organization (HSO) that provides business process solutions, service chain management, strategic consulting and leading edge technology to the healthcare industry.

Quantum has developed and deployed PWeR(TM) (, a cutting-edge, patent-pending healthcare technology system that has been designed to bridge the gaps of communication and exchange of patient information throughout the healthcare industry. To date eighteen provisional and one utility patent application have been filed in support of PWeR. The system can integrate all of the functions a physician/provider, hospital, clinic and related professionals utilize in one patient-centric, web-based platform and falls well within the economic incentives offered by the new $19 billion Stimulus Package for healthcare information technology. We believe we are positioned to be a catalyst for change as we take aim at the $700 billion inefficiency gap in the United States healthcare industry.

For more information, please visit

Certain statements contained in this news release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial uncertainties and risks in part detailed in the Company's 10-K, 10-Q, 8-K and other filings with the SEC (and amendments thereto) that may cause actual results to materially differ from projections. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by these forward-looking statements. Such risk factors include, without limitation, the ability of the Company to properly execute its business model, to raise substantial and immediate additional capital to implement its business model, to attract and retain executive, management and operational personnel, to continue growing its patient base, to negotiate favorable current debt and future capital raises, to negotiate favorable agreements with a diversified provider base and to continue to supply the services needed by its HMO clients as well as physician clients. The Company does not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.

                               RedChip Companies
                        Dave Gentry:  407.644.4256 x104
                             PR Financial Marketing
                           Jim Blackman: 713.256.0369
                            The Quantum Group, Inc.
                        Danielle Amodio:  561.798.9800

SOURCE The Quantum Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. United States Patent and Trademark Office Accepts CoolTouch's Re-examination Request for Cynosure '873 Patent
2. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
3. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
4. FDA Accepts Nuvos Resubmission For Pennsaid(R)
5. ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
6. Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute
7. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
8. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
9. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
10. Partnering With MyPyramid: NUTRIKIDS Accepts the Challenge to Help Families Step Up to Healthier Living
11. AMEX Accepts Lorus Plan to Meet AMEXs Continued Listing Standards
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... will provide scholarships for people struggling with eating disorders as a result of ... the second annual event, held at Fox Run Golf Club in Eureka, will ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a ... (TSC), as well as raising public awareness of the disorder while helping to ... third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... treatment, is offering lower prices in an early celebration of the early holiday ... promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
(Date:11/24/2015)... 24, 2015  Natera, Inc. (Nasdaq: ... testing and the analysis of circulating cell-free ... at the 27 th  Annual Piper Jaffray ... p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, ... activities and financial outlook.  ...
(Date:11/24/2015)... COMMACK, New York , 24. November ... Hersteller des Avery Breathing Pacemaker Systems, ist ... Ph.D., als Clinical Consultant bekannt geben zu ... -->   --> ... Stockholm (Schweden). Von 1984-1986 ...
Breaking Medicine Technology: